| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
REVIEW |
1 Institute of Biology and Experimental Medicine-CONICET, Vuelta de Obligado 2490, 1428 Buenos Aires, Argentina and 2 Institute of Reproductive and Developmental Biology, Imperial College Faculty of Medicine, Hammersmith Campus, Du Cane Road, London W12 0NN, UK
Correspondence should be addressed to I Huhtaniemi; Email: ilpo.huhtaniemi{at}imperial.ac.uk
The two gonadotrophins, follicle-stimulating hormone and luteinising hormone, are pivotal regulators of the development and maintenance of normal fertility by maintaining testicular and ovarian endocrine function and gametogenesis. Too low gonadotrophin secretion, i.e. hypogonadotrophic hypogonadism, is a common cause of infertility. But there are also physiological and pathophysiological conditions where gonadotrophin secretion and/or action are either transiently or chronically elevated, such as pregnancy, pituitary tumours, polycystic ovarian syndrome, activating gonadotrophin receptor mutations, perimenopause and menopause. These situations can be either the primary or secondary cause of infertility and gonadal pathologies in both sexes. Also the role of gonadotrophins as tumour promoters is possible. Recently, the possibility to combine information from genetically modified mice and human phenotypes in connection with mutations of gonadotrophin or gonadotrophin receptor genes has elucidated many less well known mechanisms involved in dysregulation of gonadotrophin function. Among the genetically modified mouse models, transgenic mice with gonadotrophin hypersecretion have been developed during the last few years. In this review, we describe the key findings on transgenic mouse models overexpressing gonadotrophins and present their possible implications in related human pathologies. In addition, we provide examples of genetic mouse models with secondary effects on gonadotrophin production and, consequently, on gonadal function.
This article has been cited by other articles:
 |
|
 |
|
  K. W. Sinkevicius, J. E. Burdette, K. Woloszyn, S. C. Hewitt, K. Hamilton, S. L. Sugg, K. A. Temple, F. E. Wondisford, K. S. Korach, T. K. Woodruff, et al. An Estrogen Receptor-{alpha} Knock-In Mutation Provides Evidence of Ligand-Independent Signaling and Allows Modulation of Ligand-Induced Pathways in Vivo Endocrinology, June 1, 2008; 149(6): 2970 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Bonnet, R Dalbies-Tran, and M A Sirard Opportunities and challenges in applying genomics to the study of oogenesis and folliculogenesis in farm animals Reproduction, February 1, 2008; 135(2): 119 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shiraishi and M. Ascoli Lutropin/Choriogonadotropin Stimulate the Proliferation of Primary Cultures of Rat Leydig Cells through a Pathway that Involves Activation of the Extracellularly Regulated Kinase 1/2 Cascade Endocrinology, July 1, 2007; 148(7): 3214 - 3225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shiraishi and M. Ascoli Activation of the Lutropin/Choriogonadotropin Receptor in MA-10 Cells Stimulates Tyrosine Kinase Cascades that Activate Ras and the Extracellular Signal Regulated Kinases (ERK1/2) Endocrinology, July 1, 2006; 147(7): 3419 - 3427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rasheed, X. Wang, Q.-T. Niu, J. Yeh, and B. Li Atm-deficient mice: an osteoporosis model with defective osteoblast differentiation and increased osteoclastogenesis Hum. Mol. Genet., June 15, 2006; 15(12): 1938 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Huhtaniemi Focus on gonadotrophin signalling Reproduction, September 1, 2005; 130(3): 261 - 262. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
